i-FACTOR

Phase 3Biologic

SSygehus Lillebaelt

i-FACTOR is one of 10 biologic programs targeting Spinal Stenosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Spinal StenosisActive, not recruiting

Spinal StenosisPhase 3

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Spinal Stenosis

#DrugCompanyPhaseTrials

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 2

Marcaine

IInnocoll

Approved

—3

Celebrex

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 4

Epidural Steroid

VVertos Medical, Inc.

Approved

1 5

Xylocaine

CCitius Pharmaceuticals, Inc.

Phase 1

—6

Decadron

QQuince Therapeutics S.p.A.

i-FACTOR

1 8

Cytotec

Pfizer

Preclinical

1 9

Esmeron

Merck & Co.

Phase 1

—10

Depomedrol

IIsfahan University of Medical Sciences

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Spinal Stenosis1 trial

The Clinical Effect of i-FACTOR® Versus Allograft in Non-instrumented Posterolateral Spondylodesis Operation in the Elderly With Spinal Stenosis Due to Degenerative Spondylolisthesis

Unknown status·SSygehus Lillebaelt·Phase 3·NCT01618435·108 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for i-FACTOR. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — i-FACTOR compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for i-FACTOR. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sygehus Lillebaelt company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: SSygehus Lillebaelt

i-FACTOR

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Spinal Stenosis1 trial

References

Drug Info

Quick Facts

Related News